Halbert Hargrove Global Advisors, LLC Alnylam Pharmaceuticals, Inc. Transaction History
Halbert Hargrove Global Advisors, LLC
- $2.02 Billion
- Q3 2025
A detailed history of Halbert Hargrove Global Advisors, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Halbert Hargrove Global Advisors, LLC holds 23 shares of ALNY stock, worth $10,902. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23Holding current value
$10,902% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding ALNY
# of Institutions
785Shares Held
115MCall Options Held
584KPut Options Held
648K-
Capital World Investors Los Angeles, CA16.8MShares$7.97 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$6.3 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.53 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.41 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.28MShares$2.03 Billion0.88% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $58.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...